LifeUnit
  • HOME
  • COMPANY
  • THERAPEUTICS
  • CONTACT
  • HOME
  • COMPANY
  • THERAPEUTICS
  • CONTACT

COMPANY

MISSION
​
Advance novel antibiotic adjuvant therapeutics to treat bacterial lung infections.
OVERVIEW
LifeUnit is a therapeutics firm focused on meeting its corporate mission by e
mploy rational molecular design to advance novel antibiotic adjuvant therapeutics. The company holds an exclusive 
license and provisional patents on several antibiotic adjuvant drug leads. These compounds show promise in significantly improving antibiotic efficacy using  in vitro studies.  Efforts are currently underway to advance high priority drug leads through pre-clinical safety studies.

MANAGEMENT
CHIEF EXECUTIVE OFFICER (CEO):   Marc Burel
CHIEF FINANCIAL OFFICER (CFO):   Dr. Mark McPike, PhD
CHIEF SCIENCE OFFICER (CSO):    Dr. Yan-Yeung Luk, PhD

BOARD OF DIRECTORS
CHAIRMAN OF THE BOARD:   Marc Burel
BOARD MEMBER (SECRETARY):   Eric Burel
BOARD MEMBER:   Dr. Mark McPike, PhD
BOARD MEMBER:   Dr. Randy Betz, MD
BOARD MEMBER:   Dr. Gordon Donald, MD
BOARD MEMBER:   Dr. Randy Clevenger, PhD

INVESTORS

​For investor opportunities in LifeUnit please contact Marc Burel (see contact page)

​

© 2020 LifeUnit, Inc
Powered by Create your own unique website with customizable templates.